NCT01152385View on ClinicalTrials.gov

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

224

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

AZD1656

Oral tablet administered twice daily during 4 months

DRUG

Placebo

administered twice daily during 4 months

Trial Locations (3)

Unknown

Research Site, Osaka

Research Site, Suita

Research Site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY